We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Microfluidic Chip-Based Device to Measure Viral Immunity

By LabMedica International staff writers
Posted on 05 Dec 2024
Print article
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well their immune system "remembers" the previous strain and reacts to the new one can vary. Currently, there is no reliable way to measure this immune “memory.” Now, new research is working to solve this issue with a device designed to assess immune memory in the blood.

When exposed to a virus, white blood cells known as B-cells activate and differentiate. Some of these B-cells become plasma cells that quickly produce antibodies to fight off the infection, while others turn into memory B-cells, remaining dormant until the same or a similar virus reappears. If the virus returns, memory B-cells can swiftly recognize it and produce antibodies to combat it. Presently, measuring circulating antibodies produced by plasma cells is possible, but antibody levels decline over time. It's far more challenging to assess the presence and effectiveness of memory B-cells, especially against new variants of the same virus. In a new project funded by the NIH, researchers from the University of California, Davis (Davis, CA, USA) and Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA) have developed a prototype device that measures memory B-cells by testing how well they can adhere to a surface while recognizing the virus under shear flow. This method, called Shear Activated Cell Sorting (SACS), is at the core of their approach.

The device works by using a microfluidic chip with tiny channels. The base of the channel is coated with the influenza virus. As white blood cells flow through these channels, memory B-cells that recognize viral proteins (antigens) will attach to the surface. By adjusting the flow rate, researchers can measure how strongly the cells adhere. As the flow rate increases, shear forces are applied to the cells, pulling them off the surface. By tracking how many cells adhere or are washed away at different flow rates, researchers can gauge their binding affinity, i.e., how well the memory cells stick to the virus. This data allows the scientists to compare how well the cells bind to the original virus they were exposed to and a new variant. The ultimate goal of this device is to provide public health labs with a tool to measure immunity to new flu variants in populations, aiding in public health decision-making. Additionally, this technology could be adapted to assess immunity against SARS-CoV-2 and other viruses.

“There’s no way to assess if the immune system is prepared for the next mutant flu virus, so we need a new vaccine every year,” said Steven George, professor of biomedical engineering at UC Davis and co-principal investigator on the grant. “We’re trying to figure out if you have white blood cells that can respond quickly to a new variant.”

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
Syphilis Screening Test
VDRL Antigen MR
New
Gastrointestinal Infection Test
REALQUALITY ETEC/EIEC
New
Automated Multiplex Immunoassay System
Bio-Plex 200 System

Print article

Channels

Molecular Diagnostics

view channel
Image: Three newly identified protein biomarkers have the potential to improve diagnostic tools for colorectal cancer (Photo courtesy of Adobe Stock)

New Protein Biomarkers to Improve Diagnostic Tools for Colorectal Cancer

Colorectal cancer is a leading cause of cancer-related deaths globally, and its incidence is expected to rise in the coming decades. This cancer begins when abnormal cells grow uncontrollably in the large... Read more

Microbiology

view channel
Image: The CRISPR-TB Blood Test provides accurate, rapid, and cost-effective diagnosis (Photo courtesy of 123RF)

CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening

Tuberculosis (TB) continues to be a leading cause of global mortality, with 10.6 million new cases and 1.6 million deaths annually. Diagnosing TB remains difficult, with smear microscopy offering only... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.